Raymond Hohl

University Professor of Oncology; Professor of Pharmacology

Raymond Hohl

Huck Affiliations

Links

Publication Tags

Neoplasms Therapeutics Acute Myeloid Leukemia Glioblastoma T Lymphocytes Pharmacology Prostatic Neoplasms Cell Line Registries Proteins Mortality Dopamine D2 Receptors Radiation Appalachian Region Clinical Trials Antipsychotic Agents Prenylation Remoxipride Prostate Cancer, Hereditary, 7 Immunoglobulin Domains Staining And Labeling B Lymphocytes Placebos Incidence Positive Regulatory Domain I Binding Factor 1

Most Recent Papers

RNAseq reveals extensive metabolic disruptions in the sensitive SF-295 cell line treated with schweinfurthins

J. S. Weissenrieder, J. D. Weissenkampen, J. L. Reed, M. V. Green, C. Zheng, J. D. Neighbors, D. J. Liu, Raymond J. Hohl, 2022, Scientific Reports

Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium-dependent, non-D<sub>2</sub> receptor-dependent, manner

Jillian S. Weissenrieder, Jessie L. Reed, George Lucian Moldovan, Martin T. Johnson, Mohamed Trebak, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2021, Pharmacology Research and Perspectives

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

Hong Zheng, Shin Mineishi, David Claxton, Junjia Zhu, Chenchen Zhao, Bei Jia, W. Christopher Ehmann, Witold B. Rybka, Seema Naik, Natthapol Songdej, Joseph J. Drabick, Raymond J. Hohl, 2021, American Journal of Hematology on p. E46-E50

Prostate cancer incidence and aggressiveness in appalachia versus non-appalachia populations in Pennsylvania by urban-rural regions, 2004–2014

Alicia C. McDonald, Emily Wasserman, Eugene J. Lengerich, Jay D. Raman, Nathaniel R. Geyer, Raymond J. Hohl, Ming Wang, 2020, Cancer Epidemiology Biomarkers and Prevention on p. 1365-1373

Spatial patterns in prostate Cancer-specific mortality in Pennsylvania using Pennsylvania Cancer registry data, 2004-2014

Ming Wang, Emily Wasserman, Nathaniel Geyer, Rachel M. Carroll, Shanshan Zhao, Lijun Zhang, Raymond Hohl, Eugene J. Lengerich, Alicia C. McDonald, 2020, BMC Cancer

Prostate cancer in Pennsylvania: The role of older age at diagnosis, aggressiveness, and environmental risk factors on treatment and mortality using data from the Pennsylvania Cancer Registry

Shirley M. Bluethmann, Ming Wang, Emily Wasserman, Chixiang Chen, Nicholas G. Zaorsky, Raymond J. Hohl, Alicia C. McDonald, 2020, Cancer Medicine on p. 3623-3633

Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML

Chenchen Zhao, Bei Jia, Ming Wang, Todd D. Schell, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Jeff M. Sivik, Raymond J. Hohl, Hui Zeng, Hong Zheng, 2020, British Journal of Haematology on p. 674-684

The Dopamine D<sub>2</sub> Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells

Jillian S. Weissenrieder, Jessie L. Reed, Michelle V. Green, George Lucian Moldovan, Emily J. Koubek, Jeffrey D. Neighbors, Raymond J. Hohl, 2020, Pharmacology on p. 19-27

First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma

Bryan G. Allen, Kellie L. Bodeker, Mark C. Smith, Varun Monga, Sonia Sandhu, Raymond Hohl, Thomas Carlisle, Heather Brown, Nancy Hollenbeck, Sandy Vollstedt, Jeremy D. Greenlee, Matthew A. Howard, Kranti A. Mapuskar, Steven N. Seyedin, Joseph M. Caster, Karra A. Jones, Joseph J. Cullen, Daniel Berg, Brett A. Wagner, Garry R. Buettner, Mindi J. TenNapel, Brian J. Smith, Douglas R. Spitz, John M. Buatti, 2019, Clinical Cancer Research on p. 6590-6597

Increased flux through the mevalonate pathway mediates fibrotic repair without injury

Jennifer L. Larson-Casey, Mudit Vaid, Linlin Gu, Chao He, Guo Qiang Cai, Qiang Ding, Dana Davis, Taylor F. Berryhill, Landon S. Wilson, Stephen Barnes, Jeffrey D. Neighbors, Raymond J. Hohl, Kurt A. Zimmerman, Bradley K. Yoder, Ana Leda F. Longhini, Vidya Sagar Hanumanthu, Ranu Surolia, Veena B. Antony, A. Brent Carter, 2019, Journal of Clinical Investigation on p. 4962-4978

Most-Cited Papers

O<sub>2</sub><sup>⋅−</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P. Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Shultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 487-500.e8

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma

A. Gronchi, B. N. Bui, S. Bonvalot, S. Pilotti, S. Ferrari, P. Hohenberger, R. J. Hohl, G. D. Demetri, A. Le cesne, P. Lardelli, I. Pérez, A. Nieto, J. C. Tercero, V. Alfaro, E. Tamborini, J. Y. Blay, 2012, Annals of Oncology on p. 771-776

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients

Edward Messing, Jason R. Gee, Daniel R. Saltzstein, Kyung Mann Kim, Anthony DiSant'Agnese, Jill Kolesar, Linda Harris, Adrienne Faerber, Thomas Havighurst, Jay M. Young, Mitchell Efros, Robert H. Getzenberg, Marcia A. Wheeler, Joseph Tangrea, Howard Parnes, Margaret House, J. Erik Busby, Raymond Hohl, Howard Bailey, 2012, Cancer Prevention Research on p. 621-630

VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML

Liru Wang, Bei Jia, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Muhammad R. Khawaja, Jeff Sivik, Junyan Han, Raymond J. Hohl, Hong Zheng, 2018, OncoImmunology

Erratum

Joshua D. Schoenfeld, Zita A. Sibenaller, Kranti A. Mapuskar, Brett A. Wagner, Kimberly L. Cramer-Morales, Muhammad Furqan, Sonia Sandhu, Thomas L. Carlisle, Mark C. Smith, Taher Abu Hejleh, Daniel J. Berg, Jun Zhang, John Keech, Kalpaj R. Parekh, Sudershan Bhatia, Varun Monga, Kellie L. Bodeker, Logan Ahmann, Sandy Vollstedt, Heather Brown, Erin P.Shanahan Kauffman, Mary E. Schall, Ray J. Hohl, Gerald H. Clamon, Jeremy D. Greenlee, Matthew A. Howard, Michael K. Schultz, Brian J. Smith, Dennis P. Riley, Frederick E. Domann, Joseph J. Cullen, Garry R. Buettner, John M. Buatti, Douglas R. Spitz, Bryan G. Allen, 2017, Cancer Cell on p. 268

Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia

Liuluan Zhu, Yaxian Kong, Jianhong Zhang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Neil D. Palmisiano, Ming Wang, Bei Jia, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hui Zeng, Hong Zheng, 2017, Journal of Hematology and Oncology on p. 124

Cancer and the dopamine D<sub>2</sub> receptor

Jillian S. Weissenrieder, Jeffrey D. Neighbors, Richard B. Mailman, Raymond J. Hohl, 2019, Journal of Pharmacology and Experimental Therapeutics on p. 111-126

Eomes<sup>+</sup>T-bet<sup>low</sup> CD8<sup>+</sup> T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia

Bei Jia, Chenchen Zhao, Kevin L. Rakszawski, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Ming Wang, Hiroko Shike, Michael G. Bayerl, Jeffrey M. Sivik, Todd D. Schell, Joseph J. Drabick, Raymond J. Hohl, Hong Zheng, 2019, Cancer Research on p. 1635-1645

Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients

Bei Jia, Liru Wang, David F. Claxton, W. Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Syed Rizvi, Hiroko Shike, Michael Bayerl, Todd D. Schell, Raymond J. Hohl, Hong Zheng, 2018, Blood Cancer Journal

Is there a future for prenyltransferase inhibitors in cancer therapy?

Sarah A. Holstein, Raymond J. Hohl, 2012, Current Opinion in Pharmacology on p. 704-709